Jefferies initiated coverage on Anthera Pharmaceuticals ANTH with a Buy rating and a $2.00 price target.
Jefferies noted, "Despite conducting a well randomized Phase II trial, and improving its Phase III odds by identifying a more targeted lupus patient population, Anthera trades at a ~$50 million EV (v our 2023 b-mod sales est of $503M). Key interim catalysts over the next 12-18 mos may be value drivers and may provide additional evidence of efficacy in lupus, and potentially provide first data in orphan IgA nephropathy."
Anthera Pharmaceuticals closed at $0.57 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in